Table 1.
Baseline characteristics of treated patients.
| Characteristics | Molnupiravir | Nirmatrelvir plus ritonavir | All |
|---|---|---|---|
| Sex Female | 8714 (48.47%) | 6027 (52.06%) | 14,741 (49.88%) |
| Sex Male | 9263 (51.53%) | 5549 (47.94%) | 14,812 (50.12%) |
| Age median (1st–3rd q) | 74.06 (62.77–82.70) | 66.31 (53.92–76.91) | 71.29 (58.95–81.07) |
| Age <55 | 2501 (13.91%) | 3114 (26.90%) | 5615 (19.00%) |
| Age 55–75 | 7015 (39.02%) | 5094 (44.00%) | 12,109 (40.97%) |
| Age >75 | 8461 (47.07%) | 3368 (29.09%) | 11,829 (40.03%) |
| Days from symptoms onset median (1st–3rd q) | 3 (2–4) | 3 (2–3) | 3 (2–4) |
| Days from positive test result median (1st–3rd q) | 2 (1–3) | 1 (1–2) | 2 (1–2) |
| Vaccination–None or not completed | 2288 (12.73%) | 1648 (14.24%) | 3936 (13.32%) |
| Fully vaccinated | 15,689 (87.27%) | 9928 (85.76%) | 25,617 (86.68%) |
| Other | 139 (0.77%) | 81 (0.70%) | 220 (0.74%) |
| ChAdOx1 | 279 (1.55%) | 217 (1.87%) | 496 (1.68%) |
| BNT162b2 | 13,372 (74.38%) | 8192 (70.77%) | 21,564 (72.97%) |
| JNJ-78436735 | 21 (0.12%) | 27 (0.23%) | 48 (0.16%) |
| mRNA-1273 | 1878 (10.45%) | 1411 (12.19%) | 3289 (11.13%) |
| Disease severity Mild | 15,392 (85.62%) | 9890 (85.44%) | 25,282 (85.55%) |
| Disease severity Moderate | 2585 (14.38%) | 1686 (14.56%) | 4271 (14.45%) |
| Saturation median (1st–3rd q) | 97 (95–98) | 97 (96–98) | 97 (96–98) |
| Comorbidities median (1st–3rd q) | 1 (1–2) | 1 (1–1) | 1 (1–2) |
| Non-Covid 19 related Oxygen-therapy | 679 (3.78%) | 299 (2.58%) | 978 (3.31%) |
| Renal function mild impairment | 898 (5.00%) | 223 (1.93%) | 1121 (3.79%) |
| Renal function moderate impairment | 951 (5.29%) | 675 (5.83%) | 1626 (5.50%) |
| Hepatic function mild impairment | 134 (0.75%) | 74 (0.64%) | 208 (0.70%) |
| Hepatic function moderate impairment | 32 (0.18%) | 21 (0.18%) | 53 (0.18%) |
| BMI 30 kg/m2 or more | 3603 (20.04%) | 2756 (23.81%) | 6359 (21.52%) |
| Chronic kidney disease | 1520 (8.46%) | 464 (4.01%) | 1984 (6.71%) |
| Uncontrolled diabetes | 2678 (14.90%) | 1211 (10.46%) | 3889 (13.16%) |
| Primary or secondary immunodeficiency | 2706 (15.05%) | 2579 (22.28%) | 5285 (17.88%) |
| Cardio-cerebrovascular disease | 9373 (52.14%) | 3618 (31.25%) | 12,991 (43.96%) |
| Severe pulmonary disease | 3505 (19.50%) | 2038 (17.61%) | 5543 (18.76%) |
| Oncological disease | 2525 (14.05%) | 2328 (20.11%) | 4853 (16.42%) |